Matthias Majetschak1, Stephen M Cohn, Udo Obertacke, Kenneth G Proctor. 1. Daughtry Department of Surgery, Divisions of Trauma and Surgical Critical Care, Ryder Trauma Center, University of Miami School of Medicine, Miami, Florida, USA. mmajetschak@med.miami.edu
Abstract
BACKGROUND: Recent studies suggest that extracellular ubiquitin could have a physiologic role in immunodepression in sepsis and trauma. The therapeutic potential of exogenous ubiquitin after trauma has not been examined. To fill this gap, we designed a series of experiments in a clinically relevant trauma model. METHODS: Forty minutes after femur fractures and hemorrhage, swine received 1.3 mg of ubiquitin per kilogram or bovine serum albumin intravenously followed by fluid resuscitation to maintain systemic hemodynamics. Leukocyte function and the immunomodulatory capacity of serum were assessed measuring endotoxin-evoked tumor necrosis factor-alpha (TNF alpha) production ex vivo. TNF alpha and ubiquitin were quantified with enzyme-linked immunosorbent assay. RESULTS: Intravenous ubiquitin had no significant hemodynamic effect in normal animals. After injury, ubiquitin significantly reduced fluid requirements by at least 60% (p < 0.05). The injury was associated with transient immunodepression, as reflected by reduced endotoxin-evoked TNF alpha production by 40% to 50%. With ubiquitin, this response remained depressed for 100 to 160 minutes (p < 0.05), but fully recovered to baseline with albumin. CONCLUSION: Ubiquitin is apparently safe and effective for reducing fluid requirements as a measure of diffuse capillary leak. This immunomodulatory property suggests a new therapeutic approach after injury in particular, and for infectious and noninfectious inflammation in general.
BACKGROUND: Recent studies suggest that extracellular ubiquitin could have a physiologic role in immunodepression in sepsis and trauma. The therapeutic potential of exogenous ubiquitin after trauma has not been examined. To fill this gap, we designed a series of experiments in a clinically relevant trauma model. METHODS: Forty minutes after femur fractures and hemorrhage, swine received 1.3 mg of ubiquitin per kilogram or bovine serum albumin intravenously followed by fluid resuscitation to maintain systemic hemodynamics. Leukocyte function and the immunomodulatory capacity of serum were assessed measuring endotoxin-evoked tumor necrosis factor-alpha (TNF alpha) production ex vivo. TNF alpha and ubiquitin were quantified with enzyme-linked immunosorbent assay. RESULTS: Intravenous ubiquitin had no significant hemodynamic effect in normal animals. After injury, ubiquitin significantly reduced fluid requirements by at least 60% (p < 0.05). The injury was associated with transient immunodepression, as reflected by reduced endotoxin-evoked TNF alpha production by 40% to 50%. With ubiquitin, this response remained depressed for 100 to 160 minutes (p < 0.05), but fully recovered to baseline with albumin. CONCLUSION: Ubiquitin is apparently safe and effective for reducing fluid requirements as a measure of diffuse capillary leak. This immunomodulatory property suggests a new therapeutic approach after injury in particular, and for infectious and noninfectious inflammation in general.
Authors: Harold H Bach; Yee M Wong; Heather M LaPorte; Richard L Gamelli; Matthias Majetschak Journal: J Trauma Acute Care Surg Date: 2016-01 Impact factor: 3.313
Authors: Vikas Saini; Daniel M Staren; Joshua J Ziarek; Zayd N Nashaat; Edward M Campbell; Brian F Volkman; Adriano Marchese; Matthias Majetschak Journal: J Biol Chem Date: 2011-07-13 Impact factor: 5.157
Authors: Stephanie L C Scofield; Suman Dalal; Kristina A Lim; Patsy R Thrasher; Christopher R Daniels; Jonathan M Peterson; Mahipal Singh; Krishna Singh Journal: Am J Physiol Heart Circ Physiol Date: 2019-01-25 Impact factor: 4.733
Authors: Todd A Baker; Jacqueline Romero; Harold H Bach; Joel A Strom; Richard L Gamelli; Matthias Majetschak Journal: Crit Care Med Date: 2012-08 Impact factor: 7.598
Authors: Todd A Baker; Jacqueline Romero; Harold H Bach; Joel A Strom; Richard L Gamelli; Matthias Majetschak Journal: Crit Care Med Date: 2012-03 Impact factor: 7.598
Authors: E Matuszczak; A Sankiewicz; W Debek; E Gorodkiewicz; R Milewski; A Hermanowicz Journal: Clin Exp Immunol Date: 2017-10-16 Impact factor: 4.330
Authors: Todd A Baker; Christopher S Davis; Harold H Bach; Jacqueline Romero; Ellen L Burnham; Elizabeth J Kovacs; Richard L Gamelli; Matthias Majetschak Journal: J Burn Care Res Date: 2012 Jan-Feb Impact factor: 1.845
Authors: Michael Bodo; Timothy Settle; Joseph Royal; Eric Lombardini; Evelyn Sawyer; Stephen W Rothwell Journal: J Clin Monit Comput Date: 2013-07-06 Impact factor: 2.502
Authors: Harold H Bach; Yee M Wong; Abhishek Tripathi; Amanda M Nevins; Richard L Gamelli; Brian F Volkman; Kenneth L Byron; Matthias Majetschak Journal: Mol Med Date: 2014-10-13 Impact factor: 6.354